X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Recognizing Hepatitis R&D on World Hepatitis Day

By Andrew Powaleny  |    July 28, 2021
Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. There are five main hepatitis viruses, with types A, B, C most common. In 2018, the Centers for Disease...   Read More

New reports shed light on key facts about medicines and affordability

By Brian Newell  |    June 8, 2021
A recently released report by IQVIA – an independent organization specializing in health care research – provides new data showing prices for brand medicines went down last year. The report offers...   Read More

How strengthening the biosimilar marketplace benefits patients

By Andrew Powaleny  |    May 18, 2021
Biologics are medicines that are made from living organisms through highly complex manufacturing processes and include a wide variety of medicines such as therapeutic proteins, monoclonal...   Read More

New report demonstrates development of new medicines relies on private sector expertise and investment

By John Corea  |    May 10, 2021
America’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. Critical to this...   Read More

West Virginia becomes the first state to lower patient costs by sharing the savings

By Scott LaGanga  |    April 20, 2021
In a historic moment for patient affordability, last week West Virginia became the first state in the nation to adopt ground-breaking legislation, HB2263, requiring insurers and their PBMs to...   Read More

Top five issues voters want addressed in the administration’s first 100 days

By Mark Keida  |    February 18, 2021
When voters cast their ballots in the 2020 election, they made clear their focus on getting COVID-19 under control and fixing the economy. However, health care was still important to many voters,...   Read More

Insurers shift medicine costs to patients with severe chronic illnesses

By Gabby Migliara  |    February 1, 2021
For many patients with complex and chronic conditions, high out-of-pocket costs for medicines pose a significant challenge. Recent research revealed a broken insurance system that fails to help...   Read More

Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds

By Gabby Migliara  |    November 19, 2020
A new analysis by IQVIA looked at three cost-sharing assistance programs and found that from 2018 to 2020, 25% to 36% of patients discontinued treatment when they faced an unexpectedly high...   Read More

Survey found insurance premiums grew faster than inflation in 2020

By Gabby Migliara  |    October 20, 2020
According to Kaiser Family Foundation’s recent survey on employer health benefits, premiums for people with employer-sponsored health insurance increased by 4% last year, faster than both the rate...   Read More

Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually

By Gabby Migliara  |    August 19, 2020
A recent analysis by IQVIA shows that chronically ill patients who used manufacturer cost-sharing assistance in 2019 saved hundreds to thousands of dollars on their out-of-pocket costs. IQVIA...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates